{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:19:44Z","timestamp":1793225984145,"version":"4.5.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009965","name":"American College of Physicians","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004830","name":"Siemens","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004830","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.chest.2020.11.027","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T22:33:46Z","timestamp":1610490826000},"page":"1107-1125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":119,"title":["Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"159","author":[{"given":"Takeshi","family":"Johkoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Travis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay H.","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ryerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Franquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Bankier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Mo","family":"Goo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"Kauczor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Richeldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia M.","family":"Schaefer-Prokop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johny","family":"Verschakelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhail","family":"Raoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey D.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Hatabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"5676","key":"10.1016\/j.chest.2020.11.027_bib2","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T\u00a0cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J\u00a0Exp Med"},{"issue":"11","key":"10.1016\/j.chest.2020.11.027_bib4","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"issue":"8","key":"10.1016\/j.chest.2020.11.027_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma [published correction appears in N Engl J Med. 2010;363(13):1290]","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1148\/radiol.2018181349","article-title":"Imaging of cancer immunotherapy: current approaches and future directions","volume":"290","author":"Nishino","year":"2019","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.chest.2020.11.027_bib7","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/JTO.0000000000000551","article-title":"Non-small-cell lung cancer: role of the immune system and potential for immunotherapy","volume":"10","author":"Carbone","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"issue":"5","key":"10.1016\/j.chest.2020.11.027_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9352","key":"10.1016\/j.chest.2020.11.027_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","article-title":"Severe acute interstitial pneumonia and gefitinib","volume":"361","author":"Inoue","year":"2003","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.chest.2020.11.027_bib10","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.chest.2020.11.027_bib11","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"10.1016\/j.chest.2020.11.027_bib12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1-related pneumonitis during cancer immunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 14","key":"10.1016\/j.chest.2020.11.027_bib13","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1200\/jco.2004.22.90140.7063","article-title":"Interstitial lung disease (ILD) during gefitinib treatment in Japanese patients with non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group","volume":"22","author":"Hotta","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2407-7-150","article-title":"Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer","volume":"7","author":"Makris","year":"2007","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.chest.2020.11.027_bib15","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1378\/chest.07-0050","article-title":"Pulmonary toxicity associated with erlotinib","volume":"132","author":"Liu","year":"2007","journal-title":"Chest"},{"issue":"16","key":"10.1016\/j.chest.2020.11.027_bib16","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","article-title":"Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib","volume":"24","author":"Ando","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.chest.2020.11.027_bib17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00130404-200509000-00010","article-title":"Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group","volume":"11","author":"Hotta","year":"2005","journal-title":"Cancer J"},{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3181ca12e0","article-title":"Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience","volume":"5","author":"Hotta","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.lungcan.2004.01.010","article-title":"Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib","volume":"45","author":"Takano","year":"2004","journal-title":"Lung Cancer"},{"issue":"suppl 14","key":"10.1016\/j.chest.2020.11.027_bib20","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.1200\/jco.2004.22.90140.7064","article-title":"Interstitial lung diseases (ILD) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC): results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey","volume":"22","author":"Seto","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib21","first-page":"100","article-title":"Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma","volume":"33","author":"Chou","year":"2010","journal-title":"Chang Gung Med J"},{"issue":"3","key":"10.1016\/j.chest.2020.11.027_bib22","first-page":"167","article-title":"Erlotinib-associated acute pneumonitis: report of two cases","volume":"14","author":"Vahid","year":"2007","journal-title":"Can Respir J"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1757-1626-3-59","article-title":"Interstitial lung disease associated to erlotinib treatment: a case report","volume":"3","author":"Del Castillo","year":"2010","journal-title":"Cases J"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1148\/radiol.2019190173","article-title":"Imaging of precision therapy for lung cancer: current state of the art","volume":"293","author":"Park","year":"2019","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib25","doi-asserted-by":"crossref","first-page":"1602419","DOI":"10.1183\/13993003.02419-2016","article-title":"Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris","volume":"50","author":"Duchemann","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2020.11.027_bib26","doi-asserted-by":"crossref","first-page":"114s","DOI":"10.1183\/09031936.01.18s320114","article-title":"Comparison of registries of interstitial lung diseases in three European countries","volume":"32","author":"Thomeer","year":"2001","journal-title":"Eur Respir J Suppl"},{"issue":"10","key":"10.1016\/j.chest.2020.11.027_bib27","first-page":"E356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J\u00a0Clin Med"},{"issue":"9","key":"10.1016\/j.chest.2020.11.027_bib28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/JTO.0b013e3181e9dbb9","article-title":"Chemotherapy-induced pulmonary toxicity in lung cancer patients","volume":"5","author":"Ryu","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"issue":"3","key":"10.1016\/j.chest.2020.11.027_bib29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ccm.2004.05.006","article-title":"Drug-induced and iatrogenic infiltrative lung disease","volume":"25","author":"Camus","year":"2004","journal-title":"Clin Chest Med"},{"issue":"4","key":"10.1016\/j.chest.2020.11.027_bib30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1055\/s-2003-42379","article-title":"Drug-induced lung disease: a pragmatic classification incorporating HRCT appearances","volume":"24","author":"Myers","year":"2003","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0033-8389(03)00109-X","article-title":"High-resolution CT of drug-induced lung disease","volume":"40","author":"Erasmus","year":"2002","journal-title":"Radiol Clin North Am"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00026","article-title":"Drug-related pneumonitis in the era of precision cancer therapy","volume":"1","author":"Nishino","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"Kroschinsky","year":"2017","journal-title":"Crit Care"},{"issue":"7","key":"10.1016\/j.chest.2020.11.027_bib35","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy [published correction appears in J Clin Oncol. 2017;35(22):2590]","volume":"35","author":"Naidoo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.chest.2020.11.027_bib36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1158\/2326-6066.CIR-15-0267","article-title":"Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer","volume":"4","author":"Nishino","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00005382-199101000-00008","article-title":"The role of chest computed tomography in the diagnosis of drug-related reactions","volume":"6","author":"Kuhlman","year":"1991","journal-title":"J\u00a0Thorac Imaging"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0272-5231(21)00674-2","article-title":"Diagnostic imaging techniques in the evaluation of drug-induced pulmonary disease","volume":"11","author":"Taylor","year":"1990","journal-title":"Clin Chest Med"},{"issue":"4","key":"10.1016\/j.chest.2020.11.027_bib39","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.chest.2019.10.048","article-title":"Transbronchial cryobiopsy for the diagnosis of interstitial lung diseases: CHEST Guideline and Expert Panel Report","volume":"157","author":"Maldonado","year":"2020","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.chest.2020.11.027_bib40","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201508-1632OC","article-title":"In-hospital mortality after surgical lung biopsy for interstitial lung disease in the united states. 2000 to 2011","volume":"193","author":"Hutchinson","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2020.11.027_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2014.12.057","article-title":"Diagnostic yield and postoperative mortality associated with surgical lung biopsy for evaluation of interstitial lung diseases: a systematic review and meta-analysis","volume":"149","author":"Han","year":"2015","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"9","key":"10.1016\/j.chest.2020.11.027_bib42","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1164\/rccm.201202-0320ST","article-title":"An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease","volume":"185","author":"Meyer","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2020.11.027_bib43","first-page":"249","article-title":"Understanding, recognizing, and managing toxicities of targeted anticancer therapies","volume":"63","author":"Dy","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"10.1016\/j.chest.2020.11.027_bib45","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 4","key":"10.1016\/j.chest.2020.11.027_bib47","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol. 2018;29(suppl 4):iv264-iv266]","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.chest.2020.11.027_bib48","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo","year":"2013","journal-title":"Respir Investig"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib49","doi-asserted-by":"crossref","first-page":"00286","DOI":"10.1183\/23120541.00286-2019","article-title":"How consistently do physicians diagnose and manage drug-induced interstitial lung disease? Two surveys of European ILD specialist physicians","volume":"6","author":"Eaden","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.chest.2020.11.027_bib50","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/CMAR.S136818","article-title":"Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis","volume":"9","author":"Chuzi","year":"2017","journal-title":"Cancer Manag Res"},{"issue":"11","key":"10.1016\/j.chest.2020.11.027_bib51","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","article-title":"Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab","volume":"23","author":"Toi","year":"2018","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.chest.2020.11.027_bib52","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.chest.2020.11.027_bib53","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.ejca.2012.03.012","article-title":"Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome","volume":"48","author":"Dabydeen","year":"2012","journal-title":"Eur J Cancer"},{"issue":"24","key":"10.1016\/j.chest.2020.11.027_bib54","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib55","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1378\/chest.07-0851","article-title":"Pulmonary complications of novel antineoplastic agents for solid tumors","volume":"133","author":"Vahid","year":"2008","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2020.11.027_bib56","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1148\/rg.2017170015","article-title":"Thoracic complications of precision cancer therapies: a practical guide for radiologists in the new era of cancer care","volume":"37","author":"Nishino","year":"2017","journal-title":"RadioGraphics"},{"issue":"4","key":"10.1016\/j.chest.2020.11.027_bib57","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1053\/crad.2001.0792","article-title":"Drug-induced lung disease: high-resolution CT and histological findings","volume":"57","author":"Cleverley","year":"2002","journal-title":"Clin Radiol"},{"issue":"5","key":"10.1016\/j.chest.2020.11.027_bib58","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00280-011-1737-2","article-title":"Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight","volume":"68","author":"Min","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.chest.2020.11.027_bib59","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1148\/radiographics.20.5.g00se081245","article-title":"Pulmonary drug toxicity: radiologic and pathologic manifestations","volume":"20","author":"Rossi","year":"2000","journal-title":"RadioGraphics"},{"issue":"6","key":"10.1016\/j.chest.2020.11.027_bib60","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00004728-199711000-00015","article-title":"The spectrum of eosinophilic lung disease: radiologic findings","volume":"21","author":"Kim","year":"1997","journal-title":"J\u00a0Comput Assist Tomogr"},{"issue":"5","key":"10.1016\/j.chest.2020.11.027_bib61","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.2214\/AJR.16.17315","article-title":"A\u00a0review of clinical and imaging findings in eosinophilic lung diseases","volume":"208","author":"Bernheim","year":"2017","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005382-199101000-00003","article-title":"Pathologic mechanisms of drug-induced lung disorders","volume":"6","author":"Pietra","year":"1991","journal-title":"J\u00a0Thorac Imaging"},{"issue":"4","key":"10.1016\/j.chest.2020.11.027_bib63","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0009-9260(05)80161-8","article-title":"High-resolution computed tomography of drug-induced lung disease","volume":"46","author":"Padley","year":"1992","journal-title":"Clin Radiol"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib64","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1378\/chest.102.1.239","article-title":"Drug-induced pulmonary disease. An update","volume":"102","author":"Rosenow","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.chest.2020.11.027_bib65","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejca.2015.10.015","article-title":"Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach","volume":"53","author":"Nishino","year":"2016","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.sult.2006.01.001","article-title":"Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations","volume":"27","author":"Silva","year":"2006","journal-title":"Semin Ultrasound CT MR"},{"issue":"4","key":"10.1016\/j.chest.2020.11.027_bib67","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2214\/ajr.175.4.1751019","article-title":"Drug-induced lung disease: high-resolution CT findings","volume":"175","author":"Ellis","year":"2000","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.chest.2020.11.027_bib68","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1148\/radiology.211.3.r99jn04859","article-title":"Acute interstitial pneumonia: thin-section CT findings in 36 patients","volume":"211","author":"Johkoh","year":"1999","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib69","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1200\/JCO.2012.43.3730","article-title":"Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer","volume":"31","author":"Tamiya","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.chest.2020.11.027_bib70","first-page":"488","article-title":"Drug-induced pulmonary disease. Part 2: noncytotoxic drugs","volume":"133","author":"Cooper","year":"1986","journal-title":"Am Rev Respir Dis"},{"issue":"6","key":"10.1016\/j.chest.2020.11.027_bib71","first-page":"1164","article-title":"Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature","volume":"14","author":"Searles","year":"1987","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.chest.2020.11.027_bib72","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jtho.2018.04.038","article-title":"Transient asymptomatic pulmonary opacities during osimertinib treatment and its clinical implication","volume":"13","author":"Lee","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.chest.2020.11.027_bib73","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2018.06.032","article-title":"Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC","volume":"123","author":"Suh","year":"2018","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.chest.2020.11.027_bib74","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2020.11.027_bib75","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cllc.2012.12.006","article-title":"Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661)","volume":"14","author":"Atagi","year":"2013","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"10.1016\/j.chest.2020.11.027_bib76","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2217\/pgs.11.38","article-title":"Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data","volume":"12","author":"Nyberg","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.chest.2020.11.027_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022062","article-title":"Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients","volume":"6","author":"Nyberg","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.chest.2020.11.027_bib78","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdw647","article-title":"High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy","volume":"28","author":"Kotake","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.chest.2020.11.027_bib79","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.jtho.2016.08.144","article-title":"Transient asymptomatic pulmonary opacities occurring during osimertinib treatment","volume":"11","author":"Noonan","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"12","key":"10.1016\/j.chest.2020.11.027_bib80","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2006.03.015","article-title":"Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus","volume":"42","author":"Duran","year":"2006","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.chest.2020.11.027_bib81","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1200\/JCO.2010.29.2235","article-title":"Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus","volume":"29","author":"Maroto","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.chest.2020.11.027_bib82","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1634\/theoncologist.2015-0033","article-title":"Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: radiographic pattern-based approach in Waldenstr\u00f6m macroglobulinemia as a paradigm","volume":"20","author":"Nishino","year":"2015","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.chest.2020.11.027_bib83","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/annonc\/mds115","article-title":"Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma","volume":"23","author":"Albiges","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.chest.2020.11.027_bib84","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.lungcan.2019.04.015","article-title":"The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: a systematic review and meta-analysis","volume":"132","author":"Suh","year":"2019","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.chest.2020.11.027_bib85","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jtho.2018.11.022","article-title":"Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib","volume":"14","author":"Gemma","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"4","key":"10.1016\/j.chest.2020.11.027_bib86","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","article-title":"Non-infectious pulmonary toxicity of rituximab: a systematic review","volume":"51","author":"Hadjinicolaou","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.chest.2020.11.027_bib87","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrclinonc.2017.88","article-title":"Monitoring immune-checkpoint blockade: response evaluation and biomarker development","volume":"14","author":"Nishino","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.chest.2020.11.027_bib88","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1378\/chest.12-1467","article-title":"Organizing pneumonia as a side effect of ipilimumab treatment of melanoma","volume":"143","author":"Barjaktarevic","year":"2013","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.chest.2020.11.027_bib89","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib90","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"issue":"suppl 9","key":"10.1016\/j.chest.2020.11.027_bib91","doi-asserted-by":"crossref","first-page":"ix125","DOI":"10.1093\/annonc\/mdv532.43","article-title":"Risk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001","volume":"26","author":"Ahn","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib92","doi-asserted-by":"crossref","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients [published correction appears in Eur Respir J. 2017;50(5):1750050]","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.chest.2020.11.027_bib93","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis [published correction appears in JAMA Oncol. 2018;4(12):1792]","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib94","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2020.11.027_bib95","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.chest.2020.11.027_bib96","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/PAS.0000000000001298","article-title":"Clinical and histopathologic features of immune checkpoint inhibitor-related pneumonitis","volume":"43","author":"Larsen","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib97","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.transproceed.2015.12.039","article-title":"Interstitial lung disease after kidney transplantation and the role of everolimus","volume":"48","author":"Solazzo","year":"2016","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1016\/j.chest.2020.11.027_bib98","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000079633","article-title":"Interstitial lung disease induced by drugs and radiation","volume":"71","author":"Camus","year":"2004","journal-title":"Respiration"},{"issue":"4","key":"10.1016\/j.chest.2020.11.027_bib99","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-152-4-201002160-00010","article-title":"Meta-analysis: effect of interactive communication between collaborating primary care physicians and specialists","volume":"152","author":"Foy","year":"2010","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.chest.2020.11.027_bib100","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1164\/rccm.200402-147OC","article-title":"Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?","volume":"170","author":"Flaherty","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.chest.2020.11.027_bib101","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1164\/rccm.200606-833OC","article-title":"Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?","volume":"175","author":"Flaherty","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib102","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40264-017-0594-2","article-title":"Safety concerns reported by patients identified in a collaborative signal detection workshop using VigiBase: results and reflections from Lareb and Uppsala Monitoring Centre","volume":"41","author":"Watson","year":"2018","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.chest.2020.11.027_bib103","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40264-013-0053-7","article-title":"The development and evaluation of triage algorithms for early discovery of adverse drug interactions","volume":"36","author":"Strandell","year":"2013","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib104","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/apjon.apjon_3_19","article-title":"Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines","volume":"6","author":"Trinh","year":"2019","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib105","article-title":"Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis","volume":"8","author":"Chen","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.chest.2020.11.027_bib106","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JCO.2005.02.5825","article-title":"First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study","volume":"24","author":"Niho","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.chest.2020.11.027_bib107","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/JTO.0b013e3181e369a8","article-title":"Severe interstitial lung disease associated with amrubicin treatment","volume":"5","author":"Yoh","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"issue":"3","key":"10.1016\/j.chest.2020.11.027_bib108","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","author":"White","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2020.11.027_bib109","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.cllc.2011.11.001","article-title":"Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer","volume":"13","author":"Togashi","year":"2012","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10.1016\/j.chest.2020.11.027_bib110","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cllc.2014.06.003","article-title":"Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib\u2014a cohort study","volume":"15","author":"Johkoh","year":"2014","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"10.1016\/j.chest.2020.11.027_bib111","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1097\/JTO.0b013e3182598abb","article-title":"Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR)","volume":"7","author":"Nakagawa","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"issue":"6","key":"10.1016\/j.chest.2020.11.027_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198886","article-title":"Pre-existing interstitial lung disease as a risk factor for pneumonitis associated with ramucirumab and paclitaxel in patients with gastric cancer: the impact of usual interstitial pneumonia","volume":"13","author":"Koyama","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.chest.2020.11.027_bib113","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1164\/rccm.201906-1202ST","article-title":"Knowledge gaps and research priorities in immune checkpoint inhibitor-related pneumonitis. An Official American Thoracic Society Research Statement","volume":"200","author":"Sears","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2020.11.027_bib114","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.lungcan.2018.10.001","article-title":"Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: a retrospective analysis","volume":"125","author":"Yamaguchi","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.chest.2020.11.027_bib115","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2018.09.015","article-title":"Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","volume":"125","author":"Cho","year":"2018","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib116","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.chest.2020.11.027_bib117","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/CAD.0b013e3283473f28","article-title":"Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports","volume":"22","author":"Yoshii","year":"2011","journal-title":"Anticancer Drugs"},{"issue":"12","key":"10.1016\/j.chest.2020.11.027_bib118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168465","article-title":"Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung cancer","volume":"11","author":"Fujimoto","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.chest.2020.11.027_bib119","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00432-016-2199-z","article-title":"Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival","volume":"142","author":"Kanaji","year":"2016","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.chest.2020.11.027_bib120","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2020.11.027_bib121","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1148\/radiol.2462070712","article-title":"Fleischner Society: glossary of terms for thoracic imaging","volume":"246","author":"Hansell","year":"2008","journal-title":"Radiology"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220353137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220353137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T23:01:02Z","timestamp":1762124462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369220353137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":119,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0012369220353137"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2020.11.027","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2020.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}